Doubling the company’s footprint in Silicon Valley, a hot spot for the promising Biologics and Advanced Therapeutics area, is a testament to Biotage’s commitment and priority to continuously invest and strengthen its presence as a supplier to the Pharma and BioPharma drug discovery and development industry.
In April 2022, Biotage established a new site for its sales, marketing, R&D and support functions in San Jose, California. The existing site will now be focusing primarily on manufacturing. This is where the development of the Biotage® PhyPrep System took place, the only automated plasmid purification platform capable of operating on the maxi, mega and giga scales.
With a near doubling of square-footage and a more suitable location at the new site for offices, product demonstrations, support services, conference facilities and laboratories, all the separate functions now have well-adapted premises at their disposal, which will support future growth. Optimizing the two San Jose premises to all different functions and getting enough space to expand in sync with a rapid growth in sales, Biotage’s Biologics and Advanced Therapeutics business area can now scale up to the next level.
The new premises offer professional demo and test labs, meeting spaces for interacting with customers, purpose-built R&D facilities, including a clean room lab, and attractive office spaces. At the same time, the old site provides space to design manufacturing premises optimally from an operational flow perspective, with the ability to bring in automation for increased efficiency.
“Our expansion in California is a testament to our commitment and priority to continuously invest in the Biologics and Advanced Therapeutics area and to strengthen our manufacturing scale up capabilities for our Biotage® PhyTips consumables. The field of Biologics and Advanced Therapeutics will be important for the healthcare of tomorrow and makes up a part of our White Tech business expected to grow further as we look ahead. Investing in premises that support this bid shows Biotage’s commitment to realize the opportunities on offer,” said Tomas Blomquist, President and CEO of Biotage.